Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2022-03-29

Clinical Trial Update: Evaluation of SAR440340 and as Combination Therapy With Dupilumab in Moderate-to-Severe Asthma Participants [Phase 2]

View source ↗

Summary

Phase 2 trial update on SAR440340 combined with dupilumab in moderate-to-severe asthma has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Dupilumab (dupilumab)
  • SAR440340 (anti-IL-33 monoclonal antibody)

Snippet

Sponsor: Sanofi | Conditions: Asthma | Phase 2 | Status: COMPLETED | Results posted: 2022-03-29